Viking Therapeutics: Biotech Stock Fluctuates Between $29 and $37 – Phase 3 Study for Obesity Candidate Underway

Viking Therapeutics Inc. (VKTX) closed at $37.48 on July 1, 2026, marking a decline of 3.92 percent from the previous day. The US biotech company is in clinical development of therapies for treating metabolic and liver diseases.

Stock Performance Shows Volatility in Q2 2026

The stock moved in a range between $29.78 on June 4 and $37.48 on July 1 during Q2 2026. On April 6, the stock traded at $33.93, representing a daily loss of 2.5 percent. On June 4, the stock rose 1.53 percent to $29.78.

Phase 3 Studies for Leading Obesity Drug Candidate

Viking Therapeutics is currently conducting Phase 3 studies for its leading obesity candidate. Phase 3 studies are clinical trials conducted on a larger patient population immediately before potential approval, designed to demonstrate a drug's efficacy and safety. According to an analysis from June 23, 2026, if development proceeds as planned, the company could have an approved drug on the market within two years.

Competition with Established Pharmaceutical Corporations

To gain market share, Viking Therapeutics will have to compete against two established pharmaceutical corporations. The obesity market is currently one of the most fiercely contested segments of the pharmaceutical industry, with multiple companies active with competing drugs.

Long-term Perspective Through 2030

Analysts evaluate the potential development of Viking stock through 2030. The valuation depends significantly on the successful completion of ongoing clinical trials and potential market approval. To date, the company has no approved products and accordingly generates no revenues from drug sales.